BNTC - NASDAQ

Benitec Biopharma Inc.

BNTC·NASDAQ

$10.70

+1.1%

HealthcareBiotechnology

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$280.84M

EPS-1.0500

P/E Ratio-10.19

Earnings Date09/28/2026

99.59M

Assets

91%

3Y+1567.0%

5Y+760.0%

10Y+570.0%

2.30M

Total Liabilities

-54%

3Y-26.0%

5Y+70.0%

10Y+192.0%

97.30M

Total Equity

106%

3Y+3276.0%

5Y+850.0%

10Y+592.0%

Benitec Biopharma Inc. Funding & Solvency Profile

BNTC · NASDAQ

Current Assets

Cash & Cash Equivalents97.74M

Net Receivables33.00K

Inventory0.00

Other Current Assets741.00K

Total Current Assets99 M

Non-Current Assets

Property, Plant & Equipment991.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets83.00K

Total Non-Current Assets1 M

Total Assets

99.59M

Financial Health Analysis

Current Ratio

54.67x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.02x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

97 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Benitec Biopharma Inc. Balance Sheet

BNTC • NASDAQ

Benitec Biopharma Inc. Balance Sheet	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jun 2017	Jun 2016	Jun 2015	Jun 2014	Jun 2013
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	97.7M	50.9M	2.5M	4.1M	19.8M	9.8M	15.7M	11.8M	13.4M	13.6M	16.7M	20.5M	28.6M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	1K	126.8K	22K	76.8K	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	97.7M	50.9M	2.5M	4.1M	19.8M	9.8M	15.8M	11.8M	13.4M	13.6M	16.7M	20.5M	28.6M
Net Receivables	33K	229K	55K	3K	25K	59K	2.5M	3M	3.4M	0.0	188.7K	115.8K	233.3K
Accounts Receivables	33K	229K	55K	3K	25K	59K	2.4M	0.0	0.0	0.0	0.0	0.0	122K
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3M	3.4M	729.6K	188.7K	115.8K	111.3K
Inventory	0.0	0.0	0.0	0.0	0.0	948K	0.0	0.0	-65.1K	111.3K	2.1M	2.6M	2.5M
Prepaids	0.0	0.0	1.2M	741K	799K	948K	501K	385.7K	281K	111.3K	74K	27K	2.5M
Other Current Assets	741K	579K	13K	14K	15K	-947K	1K	385.7K	281K	20.9K	8.4K	357.8K	30.2K
Total Current Assets	98.5M	51.7M	3.7M	4.8M	20.6M	10.8M	18.7M	15.3M	17M	14.5M	19.2M	23.6M	31.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	991K	449K	613K	993K	577K	769K	469.2K	234.3K	342K	377.9K	349.8K	429.3K	43.8K
Tax Assets	0.0	0.0	0.0	0.0	0.0	157K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	83K	87K	122K	160K	194K	-148K	9.1K	91.8K	45.3K	0.0	0.0	0.0	0.0
Total Non-Current Assets	1.1M	536K	735K	1.2M	771K	778K	478.3K	326.2K	387.3K	377.9K	349.8K	429.3K	43.8K
Total Assets	99.6M	52.2M	4.5M	6M	21.4M	11.6M	19.2M	15.7M	17.4M	14.9M	19.6M	24M	31.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	201K	1.5M	1.1M	493K	389K	483K	1.6M	580K	706.2K	538K	1.1M	573K	719.1K
Accounts Payable	201K	1.4M	1.1M	422K	274K	282K	1.5M	426.1K	133.7K	401.8K	582.9K	715.5K	522.9K
Other Payables	0.0	138K	0.0	71K	115K	201K	76K	153.9K	572.5K	136.2K	528.5K	-142.5K	196.2K
Accrued Expenses	0.0	2.7M	744K	1.4M	491K	258K	0.0	146K	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	354K	284K	275K	252K	213K	192K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	1.2M	475K	1.8M	400K	276K	203K	1.1M	1.8M	158.3K	497K	148K	972.9K	152.4K
Total Current Liabilities	1.8M	4.9M	4M	2.5M	1.4M	1.1M	2.6M	1.9M	864.5K	772.9K	1.3M	1.5M	871.5K
NON-CURRENT LIABILITIES
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	157K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	38K	0.0	0.0	0.0	0.0	0.0	35.3K	26.9K	13.4K	0.0	0.0	0.0
Total Non-Current Liabilities	495K	38K	284K	559K	0.0	213K	0.0	35.3K	26.9K	13.4K	0.0	0.0	0.0
Capital Lease Obligations	849K	284K	559K	811K	213K	405K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	2.3M	5M	4.3M	3.1M	1.4M	1.3M	2.6M	1.9M	891.4K	786.4K	1.3M	1.5M	871.5K
SHAREHOLDERS' EQUITY
Common Stock	2K	1K	0.0	0.0	1K	1K	114.9M	120.5M	119.6M	110.3M	99.4M	122M	117.9M
Additional Paid-In Capital	326.3M	238.4M	168.9M	152.5M	151.6M	128.8M	127.3M	0.0	0.0	0.0	129.6M	0.0	129.2M
Retained Earnings	-228.2M	-190.3M	-167.9M	-148.3M	-130.1M	-116.6M	-98.9M	-107.9M	-104.3M	-98.1M	-82.7M	-101.5M	-87.9M
Accumulated Other Comprehensive Income/Loss	-839K	-892K	-830K	-1.2M	-1.5M	-2M	582K	1.1M	1.3M	1.9M	1.6M	1.9M	585K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	53.2M	0.0	31.4M	0.0	-129.6M	0.0	-129.2M
Total Stockholders' Equity	97.3M	47.2M	202K	2.9M	20M	10.2M	16.6M	13.8M	16.5M	14.1M	18.3M	22.5M	30.6M
Total Equity	97.3M	47.2M	202K	2.9M	20M	10.2M	16.6M	13.8M	16.5M	14.1M	18.3M	22.5M	30.6M
SUMMARY
Total Liabilities & Equity	99.6M	52.2M	4.5M	6M	21.4M	11.6M	19.2M	15.7M	17.4M	14.9M	19.6M	24M	31.5M
Total Investments	0.0	0.0	0.0	0.0	0.0	1K	126.8K	22K	76.8K	0.0	0.0	0.0	0.0
Total Debt	849K	284K	559K	811K	213K	405K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-96.9M	-50.6M	-1.9M	-3.3M	-19.6M	-9.4M	-15.7M	-11.8M	-13.4M	-13.6M	-16.7M	-20.5M	-28.6M
Shares Outstanding	26,250,469	26,250,469	26,250,469	26,250,469	26,250,469	26,250,469	26,250,469	26,250,469	26,250,469	26,250,469	26,250,469	26,250,469	26,250,469

SEC Filings

BNTC - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 22, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	March 20, 2026	June 30, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 12, 2026	February 12, 2026	2026	View Filing
10-Q 10-Q 2025 Q4 Q4	February 12, 2026	December 31, 2025	2025	View Filing
S-3 S-3 N/A	January 30, 2026	January 30, 2026		View Filing
8-K 8-K 2025 N/A	December 02, 2025	December 01, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 14, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 14, 2025	2025	View Filing

Showing 1 to 10 of 128 filings

Related Guides

Blog Categories

Continue your BNTC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.